In The Know: Where do NSCLC brand loyalties lie in the US?

When 100 physicians from the US were asked to rate treatment options for non-small-cell lung cancer in 2018, they gave Keytruda the highest ranking (see Table 1).

Table 1: NSCLC therapies ranked by US physicians for brand satisfaction in 2018

Source: FirstWord NPS+ (US) -- Non-Small-Cell Lung Cancer (NSCLC) (2018)

Based on the Net Promoter Score (NPS) system, seven out of 13 brands featured in the 2018 survey received positive scores. The scores indicate that brand health differs greatly across the available therapies.

Due to the growing number of treatment options on the market, the 2019 surveys will be broken down into two categories, oral and biologic medications. Responses to the latest NSCLC orals survey will be available in the coming weeks and will show how this market is ranked by US physicians (click here to be notified when results are available). See Table 2 for the latest survey brand list.

Table 2: Brands included in the 2019 NSCLC (Orals) survey

FirstWord has conducted similar research in 15 competitive disease areas across the US and EU. Contact us to learn more.



To read more Sponsored Story articles, click here.